TYK-101
Autoimmune Diseases
Phase 1Active
Key Facts
About TYK Medicines
A clinical-stage biotech developing targeted small molecule therapies for oncology and immunology through structure-based drug design.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira (Adalimumab) Biosimilar | NeuClone | Early Preclinical |
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Gavocabtagene autoleucel | Astellas | Phase 1/2 |
| HCB206 | HanchorBio | Preclinical |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |
| I&I Portfolio | Third Arc Bio | Pre-clinical |